Lee, Hyunjung Park, Jinyoung Kim, Eunice EunKyeong Yoo, Young Sook Song, Eun Joo 2024-01-20T04:31:02Z 2024-01-20T04:31:02Z 2021-09-03 2016-05 1976-6696 https://pubs.kist.re.kr/handle/201004/124142 The Ubiquitin proteasome system (UPS) plays roles in protein degradation, cell cycle control, and growth and inflammatory cell signaling. Dysfunction of UPS in cardiac diseases has been seen in many studies. Cholesterol acts as an inducer of cardiac hypertrophy. In this study, the effect of proteasome inhibitors on the cholesterol-induced hypertrophic growth in H9c2 cells is examined in order to observe whether UPS is involved in cardiac hypertrophy. The treatment of proteasome inhibitors MG132 and Bortezomib markedly reduced cellular surface area and mRNA expression of beta-MHC in cholesterol-induced cardiac hypertrophy. In addition, activated AKT and ERK were significantly attenuated by MG132 and Bortezomib in cholesterol-induced cardiac hypertrophy. We demonstrated that cholesterol-induced cardiac hypertrophy was suppressed by proteasome inhibitors. Thus, regulatory mechanism of cholesterol-induced cardiac hypertrophy by proteasome inhibitors may provide a new therapeutic strategy to prevent the progression of heart failure. English KOREAN SOCIETY BIOCHEMISTRY & MOLECULAR BIOLOGY Proteasome inhibitors attenuated cholesterol-induced cardiac hypertrophy in H9c2 cells Article 10.5483/BMBRep.2016.49.5.187 1 BMB REPORTS, v.49, no.5, pp.270 - 275 BMB REPORTS 49 5 270 275 N scie scopus kci ART002109536 000383786500006 2-s2.0-84969920007 Biochemistry & Molecular Biology Biochemistry & Molecular Biology Article DEPENDENT MECHANISM DOWN-REGULATION EXPRESSION SYSTEM PATHWAY ARREST HEART CYCLE CARDIOPROTECTION CARDIOMYOPATHY Brotezomib Cholesterol-induced cardiac hypertrophy H9c2 cells MG132 Proteasome inhibitors